Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05559125
Other study ID # STSA-1002/1005-01
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date November 8, 2022
Est. completion date March 26, 2024

Study information

Verified date December 2023
Source Staidson (Beijing) Biopharmaceuticals Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open-label, single-ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 combined with STSA-1005 in healthy subjects.


Recruitment information / eligibility

Status Terminated
Enrollment 50
Est. completion date March 26, 2024
Est. primary completion date March 26, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Healthy subjects, aged = 18 but = 45, male and female; - Weight: Male=50.0kg, Female = 45kg; Body mass index: 19.0-26.0 kg/m2, inclusive; - Subjects (including their partners) must take effective contraceptive measures and have no birth plan or sperm or egg donation plan during the trial period and within 6 months after the end of the last administration; - The subjects were aware of the risks of the trial, voluntarily participated in the study and signed the informed consent form (ICF). Exclusion Criteria: - Have a history of serious disease (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immune, psychiatric or cardiovascular diseases) or have undergone any major surgery within 2 months prior to screening; - The investigators determined that abnormalities in pre-enrollment physical examinations, laboratory tests, and trial-related tests were clinically significant; - A definite history of food or drug allergies; - Positive screening test results for human immunodeficiency virus (HIV) antibodies, syphilis-specific antibody, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb); - History of tuberculosis; or combined with T-SPOT.TB results, low-dose chest CT comprehensive evaluation of tuberculosis infection; - Hemoglobin was lower than the lower limit of normal value during the screening period; - Smoking more than 5 or equivalent cigarettes per day in the 3 months before screening; - Regular drinkers in the 6 months prior to screening, i.e. those who have consumed more than 2 units of alcohol per day (1 unit =360ml beer or 45ml spirits with an alcohol concentration of 40% or 150ml wine) in the 6 months prior to screening or have a positive alcohol test result; - Subjects with a history of substance abuse within 1 year before screening or have a positive drug test result; - Blood loss or blood donation > 400ml three months before screening, or blood transfusion history within 4 weeks before inclusion; - Participate in clinical trials of new drugs or vaccines as a subject within 3 months prior to screening; - Vaccination was given within 1 month before screening or planned between the study period and 2 months after the end of the study; - Use of medications that may affect immune function in the 6 months prior to screening or any monoclonal antibody or biologic treatment in the 3 months prior to screening and use of prescription drugs/over-the-counter drugs or herbal medicines in the 14 days prior to screening; - Drink more than 5 cups of coffee, tea or cola (150ml or more per cup) daily within 3 months before screening; - Pregnant or lactating women; - A history of blood and needle sickness; - Other circumstances in which the investigator considers it inappropriate to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
STSA-1002 Injection
Intravenous injection
STSA-1005 Injection
Intravenous injection

Locations

Country Name City State
China The Second Affiliated Hospital Of Xingtai Medical College Xingtai Hebei

Sponsors (1)

Lead Sponsor Collaborator
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram?Vital Signs And Physical Examination Abnormalities. To evaluate the safety and tolerability of single intravenous administration of STSA-1002 combined with STSA-1005 in healthy adult subjects. 56 days
Secondary Maximum plasma concentration (Cmax). To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects. Up to 1344hours postdose
Secondary Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t). To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects. Up to 1344 hours postdose
Secondary Area under the plasma concentration-time curve from time 0 to infinity (AUC0-8). To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects. Up to 1344 hours postdose
Secondary Time of maximum concentration (Tmax) To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects. Up to 1344hours postdose
Secondary Elimination half-life (t1/2). To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects. Up to 1344 hours postdose
Secondary Elimination rate constant (Kel). To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects. Up to 1344 hours postdose
Secondary Clearance (CL). To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects. Up to 1344 hours postdose
Secondary Apparent volume of distribution (Vz). To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects. Up to 1344 hours postdose
Secondary Mean residence time (MRTlast). To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects. Up to 1344 hours postdose
Secondary Extrapolated area under the curve (AUC_%Extrap). To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects. Up to 1344hours postdose
Secondary Change from baseline in concentration of free C5a and anti-drug antibody. To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 combined with STSA-1005 in healthy subjects. Up to 1344 hours postdose
Secondary Change from baseline in concentration of cytokine (IL-2, IL-6, IL-8, IL-10, TNF-a, IFN-?, GM-CSF). To evaluate the effects of STSA-1002 combined with STSA-1005 on cytokine (IL-2, IL-6, IL-8, IL-10, TNF-a, IFN-?, GM-CSF). Up to 1344 hours postdose
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02664883 - Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
Completed NCT05611281 - GS3-007a Oral Solution in Healthy Subjects Phase 1
Completed NCT03457480 - Text Messages in Preventing Tobacco Use in Young Adults N/A
Completed NCT05358756 - A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers Phase 1
Completed NCT06037395 - Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects Phase 1
Active, not recruiting NCT04032106 - HPV Vaccine Intervention for Young Sexual Minority Men N/A
Completed NCT04062955 - Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants N/A
Recruiting NCT03897270 - Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects N/A
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT02960100 - mHealth Intervention in Increasing HPV Vaccinations in College Students N/A
Completed NCT03698318 - Pharmacokinetics Assessing Bioavailability of Gingerols and Shogaols of Five Ginger Extracts N/A
Completed NCT05497635 - A Study of STSA-1002 in Healthy Subjects Phase 1
Active, not recruiting NCT03303846 - Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients N/A
Completed NCT03584100 - Effect of Pneumatic Tourniquet on Arm Swelling After Lymph Node Removal N/A
Recruiting NCT05117385 - The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune) N/A
Active, not recruiting NCT05660720 - Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects Phase 1
Recruiting NCT03188848 - Dose Escalating Study of BPI-3016 in Healthy Subjects Phase 1
Completed NCT01908920 - Osteopathic Manipulative Treatment Effects on High Frequency Parameters in Healthy Subjects N/A
Active, not recruiting NCT03491176 - Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer N/A
Completed NCT03963323 - Glucosamine and Chondroitin in Gut in Preventing People From Inflammation Phase 1